| 华法林药物基因组学和个体化用药 |
| |
| 引用本文： | 彭娟,谭胜蓝,周宏灏,李智.华法林药物基因组学和个体化用药[J].中国药理学通报,2013,29(2):169-172. |
| |
| 作者姓名： | 彭娟 谭胜蓝 周宏灏 李智 |
| |
| 作者单位： | 中南大学临床药理研究所,湖南,长沙,410078 |
| |
| 基金项目： | 国家高技术研究发展计划(863计划)(No2012AA02A518);湖南省高校创新平台开放基金(No11K073) |
| |
| 摘 要： | 华法林是临床使用最广泛的口服抗凝药,其治疗窗窄,剂量个体差异大,容易发生出血或栓塞的风险。CYP2C9和VKORC1基因多态性明显影响华法林剂量。其他参与维生素摄入和循环,华法林转运的基因变异,以及microRNA也可能影响华法林剂量。该文结合国内外各种华法林稳定剂量预测模型研究,总结影响华法林剂量相关基因的最新研究进展,旨在为华法林个体化治疗提供参考和指导依据。
|
| 关 键 词： | 华法林 个体化治疗 基因多态性 剂量模型 VKORC1 CYP2C9 |
Pharmacogenomics of warfarin and its personalized treatment |
| |
| PENG Juan
,
TAN Sheng-lan
,
ZHOU Hong-Hao
,
LI Zhi.Pharmacogenomics of warfarin and its personalized treatment[J].Chinese Pharmacological Bulletin,2013,29(2):169-172. |
| |
| Authors: | PENG Juan TAN Sheng-lan ZHOU Hong-Hao LI Zhi |
| |
| Institution: | (Institute of Clinical Pharmacology,Central South University,Changsha 410078,China) |
| |
| Abstract: | Warfarin is the most widely used oral anticoagulant with narrow therapeutic window,wide inter-individual variability and high risks of bleeding or thromboembolism.Polymorphisms in CYP2C9 and VKORC1 are the major determinants of warfarin dosage requirement.Other genetic factors involving in vitamin K intake and recycle,and warfarin transportation may influence warfarin stable maintenance dosage as well.microRNA might also play a role.Based on numerous warfarin stable dosage prediction algorithms studies,this review updates the studies of warfarin pharmacogenomics and its personalized treatment,with the aim of providing evidence for clinical practice. |
| |
| Keywords: | warfarin personalized treatment genetic polymorphism dose algorithm VKORC1 CYP2C9 |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
